PBYI Insider Adrian Senderowicz Sells $194K of Stock

On June 12, 2026, Adrian Senderowicz sold 27,000 shares of Puma Biotechnology, Inc. (NasdaqGS: PBYI). The transaction, part of a planned sale, amounted to approximately $194,400, with shares priced at $7.20 each.

Insider Buying and Selling at Puma Biotechnology, Inc.

Adrian Senderowicz wasn't the only insider making moves at Puma Biotechnology on June 12. Dorval Allison sold 11,610 shares, Stuglik Brian parted with 8,100 shares, and Jay Moyes sold 22,000 shares, all at an average price of $7.20. Additionally, Troy Edward Wilson sold 10,800 shares. All these transactions were planned.

Other Institutional Activity in Puma Biotechnology

Several institutional investors have shown activity in Puma Biotechnology. Acorn Capital Advisors, LLC maintained its position with 4,131,299 shares worth about $26.4 million. BlackRock, Inc. reduced its holdings by 43,636 shares, bringing its total to 3,598,952 shares valued at around $22.9 million. Acadian Asset Management LLC added 16,936 shares, ending with 2,041,759 shares worth approximately $13 million. Renaissance Technologies LLC cut its position by 181,400 shares, leaving it with 1,942,413 shares valued at about $12.4 million. Meanwhile, American Century Companies Inc increased its stake significantly by 266,209 shares to 1,916,346 shares, valued at $12.2 million.

Puma Biotechnology, Inc. Stock Down 26.4%

Shares of Puma Biotechnology, Inc. (NasdaqGS: PBYI) recently traded at $7.33. The company boasts a market cap of about $359.9 million, with a P/E ratio of 14.73 and a forward P/E of 20.2. The stock has a 52-week range between $3.03 and $7.90. Puma's current ratio is 2.38, and its quick ratio is 2.14, with a debt-to-equity ratio of 12.42.

Recent Earnings

Puma Biotechnology reported revenue of $227.2 million, which showed a slight decline in growth at -2.6%. The company's net margin stands at 10.7%, with a return on equity of 21.6%. Its earnings per share is $0.48. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

Analysts have mixed views on Puma Biotechnology. On February 28, 2025, HC Wainwright & Co. reiterated their 'buy' rating with a $7.00 price target. TD Cowen maintains a 'hold' rating with a $4.00 target, while Barclays holds a 'sell' rating with a $2.00 target. The consensus target price among analysts stands at $5.00, based on one analyst's opinion.

About Puma Biotechnology

Puma Biotechnology, Inc. is a healthcare company based in Los Angeles, California. Founded in 2010, it focuses on developing and selling cancer treatments. Its main product, NERLYNX, is used for breast cancer treatment. Puma also works on other cancer therapies, including alisertib, targeting various types of cancer. The company operates under the leadership of CEO Alan H. Auerbach and employs 179 people.

Bottom Line

The recent insider selling at Puma Biotechnology, including Adrian Senderowicz's transaction, is part of a planned strategy and reflects ongoing activity within the company. Investors keep an eye on these moves, as well as institutional changes, to gauge market sentiment. Remember, 13F filings and insider reports are backward-looking, providing a snapshot of past actions rather than current positions.